Drug intelligence / Profile preview

mRNA-LNP Longevity-Frailty

Development stage: Preclinical
Lead developer: SirtLab
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

mRNA-LNP Longevity-Frailty is an investigational mRNA-based therapeutic encapsulated in lipid nanoparticles (LNPs) being developed by SirtLab. The therapy is designed to restore or elevate the expression of sirtuin 6 (SIRT6), a key NAD+-dependent deacetylase and mono-ADP-ribosyltransferase that plays a critical role in DNA repair, metabolic regulation, and inflammation. By boosting SIRT6 levels, the program aims to promote healthy aging, extend lifespan, and prevent or reverse age-related frailty. The asset is currently in the IND-enabling stage of development.

Other names: SIRT6 mRNA-LNPSIRT-6 mRNA-LNPSIRT 6 mRNA-LNPSIRT6-mRNA-LNPSIRT-6-mRNA-LNPSIRT 6-mRNA-LNP

Targets

SIRT6 (Sirtuin 6)

Beyond the preview

Go deeper on mRNA-LNP Longevity-Frailty.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-LNP Longevity-Frailty.